Skip to main content
Premium Trial:

Request an Annual Quote

Cypress Bioscience Test Gets Positive Medicare Reimbursement Decision

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cypress Bioscience said that it has received a positive coverage determination from a Medicare administrator for its testing service aimed at helping physicians prescribe a rheumatoid arthritis therapy.

The San Diego-based firm said that Palmetto GBA, an administrator for Medicare Part B in California, issued the positive coverage determination for its Avise PG testing service. The testing service helps physicians make decisions regarding methotrexate therapy.

"This decision to include Avise PG in the Medicare reimbursement guidelines was based upon a demonstration of the clinical validity and utility of the test, providing physicians with insight into their patient's metabolism of methotrexate," Mike Gendreau, chief medical officer of Cypress, said in a statement.

The firm noted that more than 10,000 Avise PG tests have been conducted since its launch as a testing service at the American College of Rheumatology meeting in late 2008.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.